Koss Olinger Consulting LLC Boosts Position in CRISPR Therapeutics AG $CRSP

Koss Olinger Consulting LLC grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 29.8% in the 2nd quarter, Holdings Channel.com reports. The firm owned 42,197 shares of the company’s stock after buying an additional 9,685 shares during the period. Koss Olinger Consulting LLC’s holdings in CRISPR Therapeutics were worth $2,052,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 13.3% during the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock valued at $345,929,000 after purchasing an additional 1,192,336 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of CRISPR Therapeutics by 182.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company’s stock valued at $66,452,000 after purchasing an additional 1,262,560 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of CRISPR Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock valued at $60,223,000 after purchasing an additional 33,711 shares in the last quarter. Orbis Allan Gray Ltd increased its holdings in shares of CRISPR Therapeutics by 5.9% during the 1st quarter. Orbis Allan Gray Ltd now owns 1,562,932 shares of the company’s stock valued at $53,187,000 after purchasing an additional 86,813 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of CRISPR Therapeutics by 6,769.1% during the 1st quarter. Millennium Management LLC now owns 583,733 shares of the company’s stock valued at $19,864,000 after purchasing an additional 575,235 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the completion of the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the company’s stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. The trade was a 1.27% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,213 shares of company stock valued at $3,810,458 in the last ninety days. Insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Bank of America lifted their target price on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a report on Friday, October 17th. Needham & Company LLC reissued a “buy” rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a report on Friday, October 10th. JPMorgan Chase & Co. assumed coverage on shares of CRISPR Therapeutics in a report on Thursday, September 18th. They issued an “overweight” rating and a $70.00 price target for the company. Finally, Royal Bank Of Canada boosted their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a report on Tuesday, August 5th. Ten research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and an average price target of $72.59.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $67.61 on Monday. The firm has a market cap of $6.15 billion, a PE ratio of -12.45 and a beta of 1.84. The firm has a fifty day moving average of $61.62 and a 200 day moving average of $51.52. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.18. The company had revenue of $0.89 million during the quarter, compared to analyst estimates of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm’s revenue was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.49) EPS. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.